 | • レポートコード：MRC2303G043 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界のCAR-T細胞療法市場規模が、予測期間中（2022年-2027年）CAGR more than 30％で増加すると推測されています。本書では、CAR-T細胞療法の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（Abecma、Breyanzi、Kymriah、Tecartus、その他）分析、用途別（白血病、リンパ腫、多発性骨髄腫、自己免疫疾患、その他）分析、エンドユーザー別（病院、がん治療センター、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Novartis AG、Bristol-Myers Squibb Company、Gilead Sciences, Inc. (Kite Pharma)、Johnson & Johnson、Eli Lilly and Company、Sorrento Therapeutics, Inc.、ACROBiosystemsなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のCAR-T細胞療法市場規模：種類別 - Abecmaの市場規模 - Breyanziの市場規模 - Kymriahの市場規模 - Tecartusの市場規模 - その他CAR-T細胞療法の市場規模 ・世界のCAR-T細胞療法市場規模：用途別 - 白血病における市場規模 - リンパ腫における市場規模 - 多発性骨髄腫における市場規模 - 自己免疫疾患における市場規模 - その他用途における市場規模 ・世界のCAR-T細胞療法市場規模：エンドユーザー別 - 病院における市場規模 - がん治療センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界のCAR-T細胞療法市場規模：地域別 - 北米のCAR-T細胞療法市場規模 アメリカのCAR-T細胞療法市場規模 カナダのCAR-T細胞療法市場規模 メキシコのCAR-T細胞療法市場規模 … - ヨーロッパのCAR-T細胞療法市場規模 ドイツのCAR-T細胞療法市場規模 イギリスのCAR-T細胞療法市場規模 フランスのCAR-T細胞療法市場規模 … - アジア太平洋のCAR-T細胞療法市場規模 中国のCAR-T細胞療法市場規模 日本のCAR-T細胞療法市場規模 インドのCAR-T細胞療法市場規模 … - 南米/中東のCAR-T細胞療法市場規模 ブラジルのCAR-T細胞療法市場規模 アルゼンチンのCAR-T細胞療法市場規模 サウジアラビアのCAR-T細胞療法市場規模 ・競争状況 ・市場機会・将来動向 |
The CAR T-cell therapy market is expected to register a CAGR of more than 30% over the forecast period, 2022-2027.
The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the CAR T-cell therapy market. As per a November 2021 published article titled, “Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicentre study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Haematology Association (EHA) Lymphoma Group”, CAR T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy-related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. Such studies reflect that the onset of the COVID-19 pandemic reduced the number of patients undergoing CAR-T cell therapy, negatively impacting the demand for CAR T-cell therapy. However, with the introduction of vaccines and uplifting lockdown restrictions, research and development activities have been resumed, and patient visits increased, reflecting that the market is expected to grow significantly in the coming period.
The market’s growth can be attributed to the factors such as the increasing burden of cancer worldwide and increasing research and development to develop CAR T-cell therapy.
The increasing burden of cancer is driving market growth. For instance, according to GLOBOCAN 2020, the estimated number of new cancer cases in 2020 was 19.3 million, which is estimated to reach 30.2 million by the year 2040 worldwide. As per a June 2021 update by the American Society of Clinical Oncology (ASCO), cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists can make T cells better equipped to find and kill some cancer cells. Thus, the anticipated increase in cancer cases will drive the deman dfor CAR T-cell therapy in the coming period. Additionally, the increasing research and development are contributing to the market growth. For instance, in December 2021, Novartis reported the introduction of T-Charge, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. Such developments drive the demand for CAR T-cell therapies, thereby contributing to market growth.
However, the high cost of developing CAR T-cell therapy is a major factor hindering the market growth.
Car T-Cell Therapy Market Trends
Multiple Myeloma is Expected to Observe a Significant Growth Over the Forecast Period
By application, multiple myeloma is expected to witness significant growth. Multiple myeloma is cancer that forms in a type of white blood cell called a plasma cell. It is also known as Kahler’s disease. The major factors fueling the market growth are the increasing burden of multiple myeloma, increasing research and development, and the implementation of strategic initiatives by the market players.
For instance, as per the GLOBOCAN 2020, the estimated number of new cases for multiple myeloma and immunoproliferative diseases in 2020 was about 176,000, and the number is expected to reach 290,000 by the year 2040. Additionally, as per Cancer Australia, in 2021, it was estimated that 2,423 new cases of multiple myeloma would be diagnosed in Australia (1,387 males and 1,036 females). According to the same source, in 2021, it was estimated that a person has a 1 in 117 risk of being diagnosed with multiple myeloma by age 85 (1 in 103 and 1 in 136 for females).
The increasing number of approvals is also contributing to the market growth. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson reported the United States Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Thus, the market is expected to witness significant growth over the forecast period due to the above developments.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Within North America, the United States has held the major share of the market. The major factors propelling the market growth in the country are the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.
For instance, as per the Cancer Statistics 2022 by the American Cancer Society, it was estimated that in 2022, there would be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Such a high number of cancer cases indicates the rising demand for CAR T-cell therapy in the country, thereby contributing to the market growth.
Additionally, several strategic initiatives the players implement contribute to market growth. For instance, in April 2022, Kite, a Gilead Company, reported the United States Food and Drug Administration (USFDA) approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA-approved CAR T-cell therapy to treat blood cancer.
Moreover, the growing number of investments contributes to market growth. For instance, in June 2021, Blackstone reported that funds managed by Blackstone Life Sciences had committed USD 250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company.
Thus, the market is expected to witness significant growth over the forecast period due to the abovementioned factors.
Car T-Cell Therapy Market Competitor Analysis
The CAR T-Cell therapy market is competitive with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson, and Sorrento Therapeutics, Inc., among other players.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer Worldwide
4.2.2 Increasing Invesment and Research and Development to Develop CAR T-Cell Therapy
4.3 Market Restraints
4.3.1 High Cost of Developing CAR T-Cell Therapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Abecma
5.1.2 Breyanzi
5.1.3 Kymriah
5.1.4 Tecartus
5.1.5 Yescarta
5.1.6 Others
5.2 By Application
5.2.1 Leukemia
5.2.2 Lymphoma
5.2.3 Multiple Myeloma
5.2.4 Autoimmune Disorders
5.2.5 Other Application
5.3 By End User
5.3.1 Hospitals
5.3.2 Cancer Care Treatment Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bristol-Myers Squibb Company
6.1.3 Gilead Sciences, Inc. (Kite Pharma)
6.1.4 Johnson & Johnson
6.1.5 Eli Lilly and Company
6.1.6 Sorrento Therapeutics, Inc.
6.1.7 ACROBiosystems
6.1.8 Celyad Oncology
6.1.9 Sangamo Therapeutics, Inc.
6.1.10 Servier Laboratories
6.1.11 Noile-Immune Biotech, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS